English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18260/20458 (89%)
Visitors : 6671348      Online Users : 529
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34396


    標題: Imaging biomarkers for evaluating tumor response: RECIST and beyond
    作者: Ko, Ching-Chung
    Yeh, Lee-Ren
    Kuo, Yu-Ting
    Chen, Jeon-Hor
    貢獻者: Chi Mei Med Ctr, Dept Med Imaging
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    I Shou Univ, E DA Hosp, Dept Radiol
    Kaohsiung Med Univ Hosp, Dept Med Imaging
    Univ Calif Irvine, Dept Radiol Sci, Tu & Yuan Ctr Funct Oncoimaging
    關鍵字: RECIST
    Imaging biomarker
    Tumor response
    日期: 2021
    上傳時間: 2023-11-11 11:49:31 (UTC+8)
    出版者: BMC
    摘要: Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for assessment of treatment response in solid tumors. Morphologic change of tumor size evaluated by RECIST is often correlated with survival length and has been considered as a surrogate endpoint of therapeutic efficacy. However, the detection of morphologic change alone may not be sufficient for assessing response to new anti-cancer medication in all solid tumors. During the past fifteen years, several molecular-targeted therapies and immunotherapies have emerged in cancer treatment which work by disrupting signaling pathways and inhibited cell growth. Tumor necrosis or lack of tumor progression is associated with a good therapeutic response even in the absence of tumor shrinkage. Therefore, the use of unmodified RECIST criteria to estimate morphological changes of tumor alone may not be sufficient to estimate tumor response for these new anti-cancer drugs. Several studies have reported the low reliability of RECIST in evaluating treatment response in different tumors such as hepatocellular carcinoma, lung cancer, prostate cancer, brain glioma, bone metastasis, and lymphoma. There is an increased need for new medical imaging biomarkers, considering the changes in tumor viability, metabolic activity, and attenuation, which are related to early tumor response. Promising imaging techniques, beyond RECIST, include dynamic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), diffusion-weight imaging (DWI), magnetic resonance spectroscopy (MRS), and (18) F-fluorodeoxyglucose (FDG) positron emission tomography (PET). This review outlines the current RECIST with their limitations and the new emerging concepts of imaging biomarkers in oncology.
    關聯: BIOMARK RES, v.9, n.1
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML200View/Open
    s40364-021-00306-8.pdf4628KbAdobe PDF117View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback